Cellares Raises Funding to Accelerate Cell Therapy Manufacturing Automation Device

Article

Cellares has raised $82 million to accelerate the development of its Cell Shuttle, a factory-in-a-box that allows for the automation of the process of creating highly individualized cell therapies.

Cellares Corporation, a US-based life sciences technology company, announced on May 5, 2021 that it has raised $82 million in a Series B round to accelerate the development of its Cell Shuttle, a factory-in-a-box that allows for the automation of the process of creating highly individualized cell therapies, including chimeric antigen receptor (CAR)-T therapies.

According to a company press release, the Cell Shuttle is equipped with hardware, software, robotics, and consumables, making it capable of producing 10 patient doses simultaneously, while allowing for easily transferable pre-clinical development and efficient commercial scalability.

“There are more than 450,000 patients today who could potentially benefit from CAR-T cell therapies, a number expected to grow into the millions in a few years’ time. Less than 1% of these patients are able to get access to these therapies, due to a lack of scalable cell manufacturing technologies,” said Fabian Gerlinghaus, co-founder and CEO of Cellares, in the press release.

Source: Cellares

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Behind the Headlines, Episode 10
Related Content